ProteoGenix and Bruker Daltonics Announce Collaboration for Protein Biomarker Discovery and Screening
Biomarker discovery company ProteoGenix has selected Bruker Daltonics as a strategic partner for the development of high-throughput protein biomarker discovery and mass spectrometry-based multi-analyte assay platforms, Bruker officials announced this week.
Under the collaboration, the companies will work together to implement ProteoGenix’s protein biomarker discovery methods using Bruker’s autoflex II TOF/TOF instrument. The companies also plan to increase the efficiency and throughput of protein biomarker discovery methods by employing Bruker’s magnetic bead based ClinProt platform for automatic processing of serum samples, as well as samples from other bodily fluids.
“We look forward to working with Bruker Daltonics to implement our methods on their instrumentation,” said Srinivasa Nagalla, the chief scientific officer of ProteoGenix.
Other Bruker tools that will be used for data analysis and statistical model building include the ClinProTools and ProteinScape software.
Financial terms of the collaboration were not disclosed.
NextGen Sciences Announces the Signing of New Distribution Agreements
NextGen Sciences, a protein research and molecular biology solutions company based in Cambridgeshire, UK, and Boston, announced last week that it has signed distribution agreements to further distribute its products to customers in Asia.
The agreements appoint Cold Spring Biotech in Beijing and ITS Group in Singapore as NextGen’s distribution partners. Cold Spring Biotech will sell NextGen’s products in mainland China, and ITS will sell the products in Singapore, Thailand, Malaysia, Vietnam and Indonesia.
“Over the next few months, NextGen Sciences will be introducing a suite of new products, and these agreements are part of our strategy to set up a strong network of global distributors prior to product launches,” said Grant Cameron, commercial director of NextGen Sciences.
Research and Markets Releases Report on Molecular Diagnostics Market
Research and Markets announced last week the release of a report that evaluates molecular diagnostics technologies, including polymerase chain reaction based technologies, fluorescent in situ hybridization, peptide nucleic acids, electrochemical detection of DNA, biochips, nanotechnology and proteomic technologies.
According to the report, in the year 2000, the global market for molecular diagnostics totaled approximately $3.1 billion. By 2005, it was expected to be worth $5.5 billion, and by 2010, it was expected to expand to $12 billion. This represents approximately three percent of the total diagnostics market, and approximately 12 percent of the in vitro diagnostics market.
The number of companies involved in molecular diagnostics has increased significantly during the past few years, the report states. Currently, there are more than 300 companies, mostly based in the United States, that are involved in molecular diagnostics. The report profiles 216 of these companies, along with 390 collaborations.
The report is published by PJB Publications in the United Kingdom. For more information about it, visit www.researchandmarkets.com/reports/c5189.
MorphoSys and GeneFrontier ink Marketing Collaboration
MorphoSys of Munich, Germany, and GeneFrontier of Tokyo will co-market MorphoSys’ human antibody technology in Japan, the companies said last week.
Under the multi-year agreement, the two companies will market MorphoSys’ Human Combinatorial Antibody Library technology in Japan for both research and therapeutic applications. The deal is part of MorphoSys’ effort to expand into new geographic markets.
As part of an ongoing pre-marketing agreement, MorphoSys and GeneFrontier have already conducted several research projects with Japanese partners.
Celera Genomics Licenses Cancer Targets from Proteomics Effort to Genentech
Celera Genomics and Genentech have signed a multi-year agreement to develop new cancer drugs based on targets derived from Celera’s proteomics platform, Celera said this week.
Celera will license to Genentech a number of cell-surface targets that it discovered and validated using its proteomics platform. Genentech plans to validate these further and develop drugs against them. These drugs could be antibodies, antibody fragments, proteins, or small molecule drugs.
Celera Genomics will receive progess-dependent milestone payments and royalties on sales of any drugs developed. Celera Diagnostics retains the rights to develop certain diagnostics based on the targets.
PhyNexus and Qiagen Announce New Licensing Agreement
PhyNexus, a San Jose, Calif.-based company that supplies micro volume protein purification systems said this week that it has signed a licensing agreement with Qiagen.
Qiagen is the exclusive license holder of His-tag technology patents granted to Hoffman-La Roche. Under these patent rights, it has granted PhyNexus the right to incorporate Qiagen Ni-NTA resin for the purification of His-tagged protein into their patent-pending PhyTip columns which are specifically designed for micro volume protein purification and enrichment.
“The addition of Ni-NTA as an affinity resin to capture His-tagged proteins will allow PhyNexus to expand its existing portfolio of products for micro volume purification,” said Douglas Gjerde, CEO of PhyNexus.
PNNL and Oregon Health and Science University Researchers Identify 71 HCMV Proteins
Researchers from Pacific Northwest National Laboratory and Oregon Health and Science University Human have discovered 71 proteins in human cytomegalovirus, the institutions announced Wednesday.
The discovery includes the viral and host proteins that compose the HCMV virion, according to a statement. The research was published in the October Journal of Virology.
To conduct this research, scientists used proteomics instruments and approaches that combined the high resolution separations of proteins with their identification at the same time, using mass spectrometry techniques developed in the laboratory of Richard Smith, a Battelle Fellow at Pacific Northwest National Labs.